These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 36114443

  • 1. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
    Cooper C, Wratten S, Williams-Hall R, Bookman AAM, Ndife B, Hueber W, Goswami P.
    Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
    [Abstract] [Full Text] [Related]

  • 2. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X, EULAR Sjögren's Task Force.
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [Abstract] [Full Text] [Related]

  • 3. Content Validity of Sjögren's Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren's.
    Griffiths N, Wratten S, Flynn J, Bookman AAM, Ndife B, Hueber W, Goswami P.
    Rheumatol Ther; 2022 Dec; 9(6):1559-1574. PubMed ID: 36152275
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH, Ha YJ, Kang EH, Song YW, Scofield RH, Lee YJ.
    Rheumatology (Oxford); 2021 Jun 18; 60(6):2714-2724. PubMed ID: 33188390
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W, TWINSS study group.
    Lancet; 2024 Aug 10; 404(10452):540-553. PubMed ID: 39096929
    [Abstract] [Full Text] [Related]

  • 8. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 10; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 9. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C.
    J Autoimmun; 2014 Jun 10; 51():51-6. PubMed ID: 24411404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Morel J, Pedriger A, Puechal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Zarnitsky C, Labetoulle M, Ravaud P, Mariette X.
    Arthritis Care Res (Hoboken); 2013 Aug 10; 65(8):1358-64. PubMed ID: 23436737
    [Abstract] [Full Text] [Related]

  • 12. Do the European League Against Rheumatism (EULAR) Sjögren's syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren's syndrome?
    Omma A, Tecer D, Kucuksahin O, Sandikci SC, Yildiz F, Erten S.
    Arch Med Sci; 2018 Jun 10; 14(4):830-837. PubMed ID: 30002701
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM.
    Ann Rheum Dis; 2024 Feb 15; 83(3):360-371. PubMed ID: 37932009
    [Abstract] [Full Text] [Related]

  • 15. Fatigue in Saudi Patients with Primary Sjögren's Syndrome and Its Correlation with Disease Characteristics and Outcome Measures: A Cross-Sectional Study.
    AlEnzi F, Alqahtani B, Alhamad EH, Daghestani M, Tashkandy Y, Othman N, Alshahrani K, Paramasivam MP, Halwani R, Omair MA.
    Open Access Rheumatol; 2020 Feb 15; 12():303-308. PubMed ID: 33293878
    [Abstract] [Full Text] [Related]

  • 16. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
    Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng WF, UK primary Sjögren’s Syndrome Registry.
    Rheumatology (Oxford); 2015 Apr 15; 54(4):655-9. PubMed ID: 25240612
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
    Lancet; 2022 Jan 08; 399(10320):161-171. PubMed ID: 34861168
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar 08; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

  • 19. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A, Ng WF, James K, Griffiths B, Price E, Pease C, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Gupta M, McLaren J, Cooper A, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Barone F, Fisher B, Rauz S, Richards A, Bowman S.
    Swiss Med Wkly; 2018 Mar 08; 148():w14588. PubMed ID: 29442344
    [Abstract] [Full Text] [Related]

  • 20. Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome.
    Lackner A, Bosch P, Zenz S, Horwath-Winter J, Rabensteiner DF, Hermann J, Graninger W, Stradner MH.
    Front Med (Lausanne); 2021 Mar 08; 8():660580. PubMed ID: 33937295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.